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Background: We have previously validated administrative data algorithms to identify patients with rheumatoid
arthritis (RA) using rheumatology clinic records as the reference standard. Here we reassessed the accuracy of the
algorithms using primary care records as the reference standard.
Methods: We performed a retrospective chart abstraction study using a random sample of 7500 adult patients
under the care of 83 family physicians contributing to the Electronic Medical Record Administrative data Linked
Database (EMRALD) in Ontario, Canada. Using physician-reported diagnoses as the reference standard, we
computed and compared the sensitivity, specificity, and predictive values for over 100 administrative data
algorithms for RA case ascertainment.
Results: We identified 69 patients with RA for a lifetime RA prevalence of 0.9%. All algorithms had excellent
specificity (>97%). However, sensitivity varied (75-90%) among physician billing algorithms. Despite the low
prevalence of RA, most algorithms had adequate positive predictive value (PPV; 51-83%). The algorithm of
“[1 hospitalization RA diagnosis code] or [3 physician RA diagnosis codes with ≥1 by a specialist over 2 years]” had
a sensitivity of 78% (95% CI 69–88), specificity of 100% (95% CI 100–100), PPV of 78% (95% CI 69–88) and NPV of
100% (95% CI 100–100).
Conclusions: Administrative data algorithms for detecting RA patients achieved a high degree of accuracy
amongst the general population. However, results varied slightly from our previous report, which can be attributed
to differences in the reference standards with respect to disease prevalence, spectrum of disease, and type of
comparator group.
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Validation of health administrative data algorithms for
identifying patients with different health states is an im-
portant step in accurately using these data for secondary
research [1]. Validation studies of administrative data algo-
rithms often lack consistent methodology which can also
make interpretation difficult [2]. For rheumatologic dis-
eases of relatively low prevalence, researchers often sample
patients from specialty clinics in order to increase the
prevalence of case patients in their validation samples.
However, this approach may elevate positive predictive
values (PPV) and limit the generalizability of study results
as not all patients receive continuous specialty-based care.
In order to establish the optimal approach to identifying
patients using administrative data, a population-based
sample should be used, such that the disease prevalence in
the validation cohort can approximate the prevalence of
disease in the population [3,2].
Previously, we evaluated the accuracy of administrative
data algorithms among a sample of 450 rheumatology
clinic patients, in whom the prevalence of rheumatoid
arthritis (RA) was 33%. We demonstrated that adminis-
trative data algorithms are highly accurate in identifying
RA patients under active rheumatology care [4]. While
these results are promising, it is not known whether the
algorithms we tested perform equally well amongst the
general population.
In Canada, primary care physicians act as ‘gate-keepers’
for access to specialists. Thus, primary care medical re-
cords represent a valuable resource for administrative data
validation studies, as these records provide a closer ap-
proximation of population-based disease prevalence.
Thus, our primary objective was to reassess the accur-
acy of administrative data algorithms for identification
of RA patients using diagnoses documented within the
medical records of primary care physicians, and to com-
pare our results with those of a previous study in which
we used the medical records of rheumatologists as the
reference standard [4].Methods
Setting and design
In Ontario, all 13 million residents are covered by a uni-
versal, single-payer, public health insurance including hos-
pital care and physicians’ services. A retrospective chart
abstraction study was performed among a random sample
of patients seen in primary care clinics to identify patients
with and without RA. These patients were then linked
to health administrative data to test and validate different
combinations of physician billing, hospitalization and
pharmacy data to identify RA patients within administra-
tive data. This study was approved by the Sunnybrook
Health Sciences Centre Research Ethics Board, and awaiver of patient consent was obtained as all analyses were
performed on de-identified patient records.
Participant selection
We used the Electronic Medical Record Administrative
data Linked Database (EMRALD) [5]. Clinically relevant
information contained in the patients’ charts includes all
physician office visits, information on the patient’s current
and past medical history, laboratory test results, prescrip-
tions, specialist consultation letters, discharge summaries
and diagnostic tests. We studied 83 physicians represent-
ing both urban and rural Ontario. A random sample of
7500 patients aged 20 years or older and 2,000 patients
aged 65 years or older as of December 31, 2010 were
drawn from 73,014 qualifying patients. Patients were in-
cluded if they had a valid health insurance number and
date of birth, had at least one visit in the previous year,
and were rostered to (enrolled in) the physician’s practice.
The latter criteria was required to ensure enough clinical
information to verify disease status.
Data abstraction
Using a standardized data abstraction tool, 9500 patients
had their entire medical record screened by one of five
trained abstractors to identify whether any had evidence of
inflammatory arthritis. To assess the intra- and inter-rater
reliability of chart abstractors, an initial 10% sample of
charts was abstracted a second time by the same abstractor
and once by a different abstractor. Kappa scores for inter-
and intra-rater reliability exceeded 0.85 indicating good
agreement for all five chart abstractors. Then, one abstractor
(JW) reviewed the records of patients who, based on initial
screen, were identified as possibly having inflammatory arth-
ritis. The purpose of the second screen was to verify
whether these patients had a diagnosis of RA, and whether
a rheumatologist, orthopedic surgeon or internist had
confirmed it. In addition, the abstractor verified drug history
[i.e., prescription for non-steroidal anti-inflammatory drugs
(NSAIDS), glucocorticosteroids, disease-modifying anti-
rheumatic drugs (DMARDs), or biologics], and whether
patients satisfied elements of RA classification criteria
[6,7]. Results of serology and acute phase reactants tests
were also obtained from both laboratory test fields within
the electronic medical records (EMR) and specialist con-
sultation notes. All trained chart abstractors were blinded
to the administrative data diagnoses codes for all patients.
Reference standard
Patients were classified as either RA cases or non-RA pa-
tients based on the level of evidence in the chart. The
highest levels of evidence to support an RA diagnosis were:
i) diagnosis by a rheumatologist, orthopedic surgeon, or in-
ternal medicine specialist; or ii) a primary care physician-
documented RA diagnosis with supporting evidence
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out a supporting specialist consultation note. Additionally,
patients were flagged as ‘possible RA’ cases if the record
mentioned RA but lacked supporting evidence, or if the
record had a “query RA” diagnosis. These ‘possible RA’
cases were used in a sensitivity analysis surrounding our
reference standard definition of RA in which both definite
RA and possible RA cases were grouped together.
Health administrative data sources
Once patients were classified as having or not having RA
according to our reference standard, administrative data
were obtained for these patients for the period April 1,
1991 to March 31st 2011 (the years for which administra-
tive data were available during the study period). We used
the Ontario Health Insurance Plan (OHIP) Database [8] to
identify physician billing diagnosis codes. Physicians are
reimbursed by submitting claims to OHIP for medical ser-
vices provided. One diagnosis code, representing the main
‘reason for the visit’, is provided with each claim. These
diagnoses are coded according to a modification of the 8th
revision of the International Classification of Diseases
(ICD) [9]. Hospital visits were identified using the Canadian
Institute for Health Information Discharge Abstract Data-
base (CIHI-DAD), which contains detailed information
regarding all hospital admissions, and the National Ambu-
latory Care Reporting System (NACRS), which records all
hospital-based and community-based ambulatory care for
day surgery and emergency rooms (ERs) [10]. Hospital
data prior to 2002 have diagnoses coded in ICD-9 [9] and
can contain up to 16 diagnoses recorded per hospital en-
counter. Hospitalizations and ER encounters after 2002
are coded using ICD-10, and each record contains up to
25 diagnoses per encounter. For patients aged 65 years or
older, medication exposures for DMARDS, biologics, and
glucocorticosteroids, were determined using the pharmacy
claims database of the Ontario Drug Benefit (ODB) Pro-
gram [11]. Information on physician specialty for the
billing claims was obtained by linking the Institute for
Clinical Evaluative Sciences Physician Database (IPDB)
with the OHIP database [12]. Musculoskeletal specialists
were identified as rheumatologists, orthopedic surgeons,
and internal medicine specialists. The OHIP Registered
Persons Database (RPDB) contains a single unique record
for each health care beneficiary that enables the linkage of
these datasets in an anonymous fashion using encrypted
health insurance numbers [13]. All data reside and all ana-
lyses were performed at the Institute for Clinical Evalu-
ative Sciences (www.ices.on.ca).
Test methods
Results are reported using the modified Standards for
Reporting of Diagnostic Accuracy (STARD) criteria [14,3].
Our methodological approach and study conduct complieswith recent recommendations on the reporting and study
design of administrative data validation studies [2].
Algorithm testing
Algorithms were derived using combinations of physician
billing diagnosis (ICD 714), primary and secondary hos-
pital discharge diagnosis (ICD9 714; ICD10 M05-M06),
prescription drug claims (for DMARDs, biologics, and glu-
corticosteroids), by varying windows between diagnosis
codes or the period in which diagnosis codes appeared,
and whether the services were rendered by a musculoskel-
etal specialist. Additionally, we tested algorithms with
exclusion criteria in which diagnosis codes for ‘other
rheumatology conditions’ appeared after a diagnosis of
RA, or for which an RA diagnosis code was not provided
when a patient was seen by a rheumatologist. The ‘other
rheumatology diagnoses’ included: osteoarthritis, gout,
polymyalgia rheumatica, other seronegative spondyloar-
thropathy, ankylosing spondylitis, connective tissue disorder,
psoriasis, synovitis/tenosynovitis/bursitis, and vasculitis.
All algorithms were tested on the entire sample except
those involving prescription drug claims, which were lim-
ited to patients aged 65 years and older. The algorithms
were applied to all administrative data for the study period
(up to March 31, 2011).
Statistical analysis
Descriptive statistics were used to characterize the study
population. We computed the sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value
(NPV) of each algorithm with corresponding 95% confi-
dence intervals (CI). Details of the how these measures
were computed are illustrated in Table 1 [2]. Algorithms
were first ranked according to highest PPV, followed by
highest sensitivity and specificity. All analyses were per-
formed on de-identified data using SAS version 9.2 (SAS
Institute, Cary, North Carolina).
Sample size
We estimated that we would require at least 50 individuals
with RA in order to obtain sensitivity and specificity esti-
mates of approximately 85% with a precision that ensured
that the 95% CIs were within +/− 5% of the estimate. As-
suming an overall RA prevalence of 0.7-1% in the adult
population, we required a study cohort comprising at least
7000 adult patients. Taking into account that RA preva-
lence increases in a mature population (>65 years of age)
[15], we estimated that we would need a random sample
of approximately 2000 additional seniors in order to have
enough RA cases aged >65 to ensure precise results when
we restrict our analysis to seniors and incorporate drug
prescriptions in our administrative algorithm. Therefore,
stratified random sampling was performed to obtain 7500
patients aged 20 years and older for our primary analysis
Table 1 Methods to computing measures of diagnostic accuracy
Reference standard Pre−test prevalence ¼ TP þ FNTP þ FP þ FN þ TN
RA cases Non-cases
Administrative data
Positive True Positive (TP) False Positive (FP) PPV ¼ TPTPþFP
Negative False Negative (FN) True Negative (TN) NPV ¼ TNFN þ TN
Sensitivity ¼ TPTP þ FN Specificity ¼ TNFP þ TN Post−test Prevalence ¼ TP þ FPTP þ FP þ FN þ TN
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our analyses restricted to seniors.Results
The 83 physicians included in this study were in practice
an average of 18.4 years, and they had used an EMR an
average of 5.9 years (standard deviation, SD 3.2). The
average patient time on the EMR was 5 years (range 2–
23.5). Analyses were performed on 7500 patients aged
20 years and older and 3426 patients aged 65 years and
older. The average age of the 7500 patients in the adult
cohort was 49 (SD 17, range: 20–98) years.
Using our reference standard definition, we identified
69 RA patients for a lifetime RA prevalence of 0.9% for
patients aged 20 years and older (Figure 1). Amongst the
RA cases, almost two thirds were female (64%) and the
average age was 61.9 (SD 13.7) years. Amongst the 3426
patients aged 65 years and older, 63 (1.8%) patients had
RA. Sixty-five percent were female and their average age
was 76.3 (SD 6.8) years.Patients (aged  ≥ 20y) m
inclusion criteria
n=73,014
Random Sample of Pa
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Figure 1 Flow diagram of selection of study participants.Clinical characteristics of the 69 RA patients are shown
in Table 2. Most RA patients (86%) had documentation of
an RA diagnosis by a specialist. Most RA patients also had
documentation of bilateral joint involvement and small
joint synovitis. Seropositivity (for rheumatoid factor and/
or anti-ccp) was documented for 39% of RA patients and
elevated acute phase reactants (i.e. erythrocyte sedimenta-
tion rate or c-reactive protein) were documented for 45%.
DMARDs were the most commonly reported RA drug ex-
posures and were present in 80% of patients.
Sensitivity, specificity, and predictive values for selected
administrative data algorithms are reported in Table 3. Al-
gorithms selected for reporting are based on those com-
monly in use by researchers. Access to the complete set of
over 100 additional algorithms is available through the
corresponding author. All algorithms had excellent specifi-
city (97-100%). However, the sensitivity of the physician
billing algorithms varied (77-90%). Despite the low preva-
lence of RA in the primary care records, algorithms for
identifying RA patients had at least modest PPV (51-83%),
which improved substantially with the requirement forNon-RA 
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Table 2 Clinical characteristics and drug exposures for RA
patients
Characteristics Aged 20 and
older n = 69
Age (years), mean (SD) 61.9 (13.7)
Female gender 64%
Diagnosis provided by a Specialist 86%
Morning Stiffness 65%
Hand joint involvement (>1 swollen wrist, MCP, or
PIP joint)
67%
Symmetric Arthritis (PIPs, MCPs, or MTPs) 65%
Rheumatoid Nodules 19%
Radiographic changes typical of RA 22%
2-10 medium-large joint involvement (shoulders,
elbows, hips, knees, ankles)
39%
1-3 small joint involvement (MCPs, PIPs, 2nd-5th
MTPs, thumb IPs, wrists)
54%
4-10 small joint involvement (as above) 51%
>10 joint involvement (as above) 26%
RF or ACPA positive 39%
Elevated ESR or CRP 45%
NSAID/COXIB use* 77%





*Prescribed by any physician (specialist or primary care physician).
Abbreviations: MCPs metacarpophalangeal joints, PIPs proximal interphalangeal
joints, MTPs metatarsophalangeal joints, IPs interphalangeal joints, DMARD
disease-modifying anti-rheumatic drug, NSAID non-steroidal anti-inflammatory
drug, COXIB COX-2 selective inhibitor, RF Rheumatoid Factor, ACPA anti–
citrullinated protein antibody, ESR erythrocyte sedimentation rate, CRP
C-reactive protein.
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the observation window for diagnosis codes had little im-
pact on the accuracy of the algorithms. The addition of
time restrictions between diagnosis codes (e.g., diagnosis
codes ≥ 8 weeks apart) and exclusion criteria also did not
improve algorithm performance.
Among seniors (Table 4), the requirement for an RA
drug exposure slightly improved the PPV, although the
95% CIs overlapped with those for the algorithms ex-
cluding RA drugs.
After ranking algorithms by our a priori definition, the
algorithm to meet this criteria was: “[1 hospitalization
RA code] OR [3 physician RA diagnosis codes (claims)
with ≥1 by a specialist in a 2 year period]” which had a
sensitivity of 78% (95% CI 69–88), specificity of 100%
(95% CI 100–100), PPV of 78% (95% CI 69–88) and
NPV of 100% (95% CI 100–100).
When we varied the definition of our reference stand-
ard to include all possible RA patients, the prevalence
increased from 0.9% to 1.3%. When the algorithms wereretested including these patients, there was a trend to-
ward decreasing sensitivity. There was no effect on spe-
cificity or NPV, however PPV slightly increased with
more RA patients classified in the reference standard.
Discussion
Our findings show that, in the primary care setting, most
administrative data algorithms for RA had high specificity.
We found that incorporating specialist diagnosis codes in-
creased PPV (51-83%), and requiring multiple RA codes
increased both specificity and PPV. However increasing
the duration of the observation window to identify RA
codes or varying the time between RA codes had little im-
pact on algorithm performance. In addition, incorporating
RA drugs only slightly improved PPV, hospitalization
codes alone had poor sensitivity, and use of more complex
cases definitions involving exclusion criteria did not im-
prove algorithm performance.
Overall, we have comprehensively evaluated the accuracy
of administrative data algorithms that were measured rela-
tive to the reference standards of two independent valid-
ation samples using the diagnoses documented within
medical charts of rheumatologists (previously reported) [4]
and family physicians (reported here). After testing admin-
istrative data algorithms and ranking algorithms according
to performance characteristics, the optimal algorithm
identified for identifying RA patients in both samples was
identical. The algorithm of “[1 hospitalization RA code]
OR [3 physician RA diagnosis codes with ≥1 RA code by a
specialist in a 2 year period]” had a sensitivity of 78%, spe-
cificity of 100%, PPV of 78% and NPV of 100% when using
our primary care reference standard. When we independ-
ently validated this algorithm among a random sample of
450 patients seen in rheumatology clinics [4], it demon-
strated a sensitivity of 97%, specificity of 85%, PPV of 76%
and NPV of 98%.
While we identified the same algorithm as optimal in
both settings, we did not achieve identical results, which
can be attributed to differences in the study samples (ref-
erence standards) with respect to disease prevalence,
spectrum of disease, and type of comparator group. For
example, 33% of patients had RA within the rheumatology
sample [4] versus 0.9% within the primary care sample.
The spectrum of disease (clinical characteristics) in our
rheumatology sample included contemporary RA patients
under active rheumatology care and treatment, compared
to patients with a lifetime RA diagnosis who may only be
currently receiving active primary care. The type of com-
parator group (non-cases) in our rheumatology study in-
volved patients with other rheumatologic diagnoses, in
contrast to our primary care patients who are healthy or
have other diagnoses.
In both samples, algorithm sensitivity was computed
only among study subjects with RA, and specificity was
Table 3 Test characteristics of multiple algorithms among patients ≥ 20 y








1 H ever 15 7429 54 2 0.2% 22 (12–32) 100 (100–100) 88 (73–100) 99 (99–100)
1 H ever OR 1 ER ever 16 7427 53 4 0.3% 23 (13–33) 100 (100–100) 80 (63–98) 99 (99–100)
1 P ever 62 7188 7 243 4.1% 90 (83–97) 97 (96–97) 20 (16–25) 100 (100–100)
1 P ever by a specialist 56 7377 13 54 1.5% 81 (72–90) 99 (99–100) 51 (42–60) 100 (100–100)
2 P by any physician in 1 YR 58 7363 11 68 1.7% 84 (75–93) 99 (99–99) 46 (37–55) 100 (100–100)
2 P by any physician in 2 YR 58 7359 11 72 1.7% 84 (75–93) 99 (99–99) 45 (36–53) 100 (100–100)
2 P by any physician in 3 YR 58 7352 11 79 1.8% 84 (75–93) 99 (99–99) 42 (34–51) 100 (100–100)
3 P by any physician in 1 YR 55 7398 14 33 1.2% 80 (70–89) 100 (99–100) 63 (52–73) 100 (100–100)
3 P by any physician in 2 YR 55 7395 14 54 1.2% 80 (70–89) 100 (99–100) 60 (50–71) 100 (100–100)
3 P by any physician in 3 YR 55 7393 14 38 1.2% 80 (70–89) 100 (99–100) 59 (49–69) 100 (100–100)
2 P with ≥ 1 P by a specialist in 1 YR 54 7404 15 27 1.1% 78 (69–88) 100 (100–100) 67 (56–77) 100 (100–100)
2 P with ≥ 1 P by a specialist in 2 YR 54 7404 15 27 1.1% 78 (69–88) 100 (100–100) 67 (56–77) 100 (100–100)
2 P with ≥ 1 P by a specialist in 3 YR 54 7401 15 30 1.1% 78 (69–88) 100 (100–100) 64 (54–75) 100 (100–100)
3 P with ≥ 1 P by a specialist in 1 YR 53 7419 16 12 0.9% 77 (67–87) 100 (100–100) 82 (72–91) 100 (100–100)
3 P with ≥ 1 P by a specialist in 2 YR 53 7418 16 13 0.9% 77 (67–87) 100 (100–100) 80 (71–90) 100 (100–100)
3 P with ≥ 1 P by a specialist in 3 YR 53 7418 16 13 0.9% 77 (67–87) 100 (100–100) 80 (71–90) 100 (100–100)
(1 H ever) OR (2 P with≥ 1 P by a specialist
in 1 YR)
55 7403 14 28 1.1% 80 (70–89) 100 (100–100) 66 (56–76) 100 (100–100)
(1 H ever) OR (2 P with≥ 1 P by a specialist
in 2 YR)
55 7403 14 28 1.1% 80 (70–89) 100 (100–100) 66 (56–76) 100 (100–100)
(1 H ever) OR (2 P with≥ 1 P by a specialist
in 3 YR)
55 7400 14 31 1.1% 80 (70–89) 100 (99–100) 64 (54–74) 100 (100–100)
(1 H ever) OR (3 P with ≥1 P by a specialist
in 1 YR)
54 7417 15 14 0.9% 78 (69–88) 100 (100–100) 79 (70–89) 100 (100–100)
(1 H ever) OR (3 P with ≥1 P by a specialist
in 2 YR)
54 7416 15 15 0.9% 78 (69–88) 100 (100–100) 78 (69–88) 100 (100–100)
(1 H ever) OR (3 P with ≥1 P by a specialist
in 3 YR)
54 7416 15 15 0.9% 78 (69–88) 100 (100–100) 78 (69–88) 100 (100–100)
(1 H ever) OR (2 P≥ 8 weeks apart in 2 YR,
no exclusions*
57 7378 12 53 1.5% 83 (74–92) 99 (99–100) 52 (43–61) 100 (100–100)
(1 H ever) OR (2 P≥ 8 weeks apart in 2 YR)
excluding Case A or Case B
41 7401 28 30 0.9% 59 (48–71) 100 (100–100) 58 (46–69) 100 (100–100)
(1 H ever) OR (2 P≥ 8 weeks apart in 3 YR)
excluding Case A or Case B
41 7396 28 35 1.0% 59 (48–71) 100 (99–100) 54 (43–65) 100 (100–100)
(1 H ever) OR (2 P≥ 8 weeks apart in 4 YR)
excluding Case A or Case B
43 7394 26 37 1.1% 62 (51–74) 100 (99–100) 54 (43–65) 100 (100–100)
(1 H ever) OR (2 P≥ 8 weeks apart in 5 YR)
excluding Case A or Case B
44 7390 25 41 1.1% 64 (52–75) 99 (99–100) 52 (41–62) 100 (100–100)
(1 H ever) OR (2 P≥ 8 weeks apart in 2 YR)
excluding Case A
41 7402 28 29 0.9% 59 (48–71) 100 (100–100) 59 (47–70) 100 (100–100)
All Ages: N = 7500 patients (69 RA and 7431 non-RA); # = Post-test prevalence; TP = True Positive; TN = True Negative; FN = False Negative; FP = False Positive
H: Hospitalization diagnosis code; P = physician diagnosis code; Specialist = rheumatologist, internal medicine, orthopedic surgeon; *Exclusions: Case A: Patients
with ≥ 2 P with another rheumatology diagnosis subsequent to an RA diagnosis OR Case B: Patients for which the diagnosis of RA was not confirmed by a
specialist. Other rheumatology diagnoses include: Osteoarthritis (715), Gout (274, 712), Polymyalgia Rheumatica (725), other seronegative spondyloarthropathy
(721), Ankylosing spondylitis (720), psoriasis (696), synovitis/tenosynovitis/bursitis (727), connective tissue disorder (710), vasculitis (446), others (716; 718; 728;
727; 728; 729; 781).
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cificity do not depend on the prevalence of the RA in
the study population, but they can vary across popula-
tions [16]. For example, sensitivity or our administrativedata algorithm was excellent (>97%) at identifying con-
temporary RA under active rheumatology care [4]. In
contrast, sensitivity was moderately good (78%) at iden-
tifying RA patients with a lifetime diagnosis of RA (who
Table 4 Test characteristics of multiple algorithms among patients aged ≥ 65 y








1 P AND ≥1 Rx ever 53 3248 10 115 4.9% 84 (75–93) 97 (96–97) 32 (25–39) 100 (100–100)
2 P AND ≥1 Rx ever 51 3318 12 45 2.8% 81 (71–91) 99 (98–99) 53 (43–63) 100 (99–100)
2 P≥ 60 days apart AND ≥1 RX ever 49 3320 14 43 2.7% 78 (68–88) 99 (98–99) 53 (43–64) 100 (99–100)
(1 H ever) OR (2 P AND ≥1 Rx in 1 YR) 52 3337 11 26 2.3% 83 (73–92) 99 (99–100) 67 (56–77) 100 (100–100)
(1 H ever) OR (2 P AND ≥1 Rx in 2 YR) 52 3335 11 28 2.3% 83 (73–92) 99 (99–100) 65 (55–76) 100 (100–100)
(1 H ever) OR (2 P AND ≥1 RX in 3 YR) 52 3332 11 31 2.4% 83 (73–92) 99 (99–99) 63 (52–73) 100 (100–100)
(1 H ever) OR (2 P with≥ 1 P by specialist
AND ≥1 Rx in 1 YR)
52 3347 11 16 2.0% 83 (73–92) 100 (99–100) 77 (66–87) 100 (100–100)
(1 H ever) OR (2 P with≥ 1 P by specialist
AND ≥1 Rx in 2 YR)
52 3346 11 17 2.0% 83 (73–92) 100 (99–100) 75 (65–86) 100 (100–100)
(1 H ever) OR (2 P with≥ 1 P by specialist
AND≥ 1 Rx in 3 YR)
52 3345 11 18 2.0% 83 (73–92) 100 (99–100) 74 (64–85) 100 (100–100)
(1 H ever) OR (3 P AND≥ 1 Rx in 1 YR) 47 3346 16 17 1.9% 75 (64–85) 100 (99–100) 73 (63–84) 100 (99–100)
(1 H ever) OR (3 P AND≥ 1 Rx in 2 YR) 48 3342 15 21 2.0% 76 (66–87) 99 (99–100) 70 (59–80) 100 (99–100)
(1 H ever) OR (3 P AND≥ 1 Rx in 3 YR) 48 3342 15 21 2.0% 76 (66–87) 99 (99–100) 70 (59–80) 100 (99–100)
(1 H ever) OR (3 P with≥ 1 P by specialist
AND≥ 1 Rx in 1 YR)
47 3351 16 12 1.7% 75 (64–85) 100 (99–100) 80 (69–90) 100 (99–100)
(1 H ever) OR (3 P with≥ 1 P by specialist
AND≥ 1 Rx in 2 YR)
48 3349 15 14 1.8% 76 (66–87) 100 (99–100) 77 (67–88) 100 (99–100)
(1 H ever) OR (3 P with≥ 1 P by specialist
AND≥ 1 Rx in 3 YR)
48 3348 15 15 1.8% 76 (66–87) 100 (99–100) 76 (66–87) 100 (99–100)
Seniors 65+: N = 3426 patients (63 RA and 3363 non-RA); # = Post-test prevalence; TP = True Positive; TN = True Negative; FN = False Negative; FP = False Positive;
H: Hospitalization code; P = physician diagnosis code; Specialist = rheumatologist, internal medicine, orthopedic surgeon; Rx refers to drug exposures: oral
corticosteroid, disease-modifying anti-rheumatic drug (DMARD) or biologic; DMARDs included: Azathioprine, Chloroquine, Cyclophosphamide, Cyclosporine, Gold,
Minocycline; and Biologics included: Etanercept, Adalimumab, Infliximab, Certolizumab, Golimumab; Abatacept, Anakinra, Rituximab, Tocilizumab.
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patients whose symptoms may have resolved, and are no
longer seeking RA care). When we varied our definition of
RA based on levels of evidence in the primary care charts
(i.e., varied the spectrum of disease in our cohort), more
strict definitions of RA according to the reference stand-
ard increased sensitivity, whereas more liberal definitions
of RA (such as allowing any mention of RA with no sup-
porting evidence, or those with a query RA diagnosis) de-
creased sensitivity of the administrative data algorithms.
Thus, defining an a priori reference standard to classify in-
dividuals with RA has implications for validation study
methodology. For instance, patients who fulfill strict clas-
sification criteria, such as the 1987 RA criteria [17], may
have more advanced disease (patients with longer disease
duration, or more active disease requiring multiple phys-
ician visits) and have a greater chance of being detected
by administrative data algorithms. This finding was also
observed in a review of studies that tested administrative
data algorithms amongst RA patients who were required
to meet strict classification criteria: these patients had a
higher sensitivity in comparison to patients who were clas-
sified by more liberal criteria (such as an RA diagnosis
documented in the medical record) [2].On the other hand, as specificity is computed only
among those without RA, the type of patients included
in the non-RA comparator group (as defined by the ref-
erence standard) can influence the estimates of specifi-
city. The lower specificity observed amongst non-RA
patients in the rheumatology clinic study (85% versus
100% specificity observed amongst the primary care
sample), is reflective of the patients without RA in the
rheumatology clinic sample are individuals with other
rheumatologic diagnoses (which may resemble RA, and/or
who at one point in time may have been considered a pos-
sible RA patient, and then evolved into a more clear diag-
nosis, such as systemic lupus). In contrast, the comparator
group of individuals without RA in our primary care sam-
ple included patients with other conditions (unrelated to
RA), which improved the specificity. This observation has
implications for research that seeks to identify population-
based algorithms with high specificity. Furthermore, it em-
phasizes the importance of reporting the characteristics of
the patients in the comparator group to inform proper in-
terpretation of specificity estimates.
While sensitivity and specificity are dependent on the
characteristics of patients with and without the disease, re-
spectively, predictive values depend on disease prevalence,
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finding of our study is that our optimal algorithm had vir-
tually the same PPV (78%) in both studies. Our primary
care sample had an RA prevalence reflective of that of the
general population (0.9%) in comparison to the rheuma-
tology sample which had a study RA prevalence of 33%
[4]. However, there was variation among the PPV esti-
mates ranging from 51-83% amongst our primary care
sample, and ranging from 55-80% amongst the rheumatol-
ogy sample. The PPV estimates improved substantially
with the requirement of increasing the number of diagno-
sis codes and including musculoskeletal specialist codes
for RA. In addition to differences in prevalence estimates
in both samples, specificity differed, with all algorithms
tested within our primary care sample achieving very high
(≥97%) specificity. In general, for conditions that are
present in a minority of the study population (such as our
primary care sample), specificity has a greater impact than
sensitivity on PPV. However specificity alone is not the
sole factor increasing PPV amongst the primary care sam-
ple, as all algorithms with high specificity would have
moderately good PPV. A more likely explanation is that
the preferred algorithm identified fewer false positives in
both settings, as having fewer false positives increases
PPV. This is likely owing to the nature of RA manage-
ment, which often involves referral to a specialist, frequent
physician visits and a non-curative long disease course.
These observations suggest that patients with prevalent
(long-term) chronic conditions may have a higher probabil-
ity of being identified by the use of similar administrative
data algorithms owing to the disease course, management
practices, and frequency of physician visits. This finding
may be further supported by the concordance between our
results and those from algorithms for case ascertainment
of diabetes [17], hypertension [18], and other chronic dis-
eases with substantially higher prevalence than RA.
This study has both strengths and limitations. Patients
were randomly sampled from primary care physician re-
cords and we tested many more permutations of admi-
nistrative data algorithms than other studies. We also
conducted rigorous chart reviews. However, misclassifica-
tion of RA is a potential risk if there is lack of documenta-
tion in the medical record, such as a failure to capture all
specialist consultation notes. Further, clinical characteris-
tics for the RA patients may be under-documented in pri-
mary care clinical records. Recognizing this challenge, we
opted to include all physician-reported diagnoses to define
our reference standard, as our retrospective study design
can make it difficult to determine true disease status.
However, our present findings extend those of previous re-
search performed using the General Practice Research
Database, which also found a sensitivity of 80% for pa-
tients with 3 RA diagnosis codes [19]. Further, as the pur-
pose of our study was to test the accuracy of algorithmsfor classifying RA patients within administrative data, we
were unable to confirm the validity of the diagnosis of RA
itself (whether doctors were correctly diagnosing RA).
However, the majority of RA patients had specialist notes
to confirm RA.
Another potential limitation is that our findings are de-
rived from patients who have a regular source of primary
care. Consequently, our results may not be generalizable
to patients who do not have a regular primary care phys-
ician. Although almost ten million Ontarians (that is, over
80% of the population) are now rostered to a primary care
physician [20,21], we acknowledge this limitation and
opted to include inpatient RA diagnosis codes in our final
preferred administrative algorithm, even though alone
these codes had low sensitivity (22%) and offered little im-
provement over physician-billing algorithms. The addition
of an inpatient RA code to “3 physician RA claims with ≥1
by a specialist in a 2 year period” may subsequently in-
crease the sensitivity of our algorithm when it is applied to
the entire population since hospitalization data may be
needed to pick up RA cases who either have no regular
physician, or who are followed by the approximately 5% of
Ontario physicians who are salaried (and who do not ne-
cessarily contribute to billing data) [22].
In addition, while the overall goal was to recommend
the optimal algorithm for use in Ontario, we report the re-
sults of numerous algorithms so that researchers can be
better informed by choosing the case definition best suit-
able for their study populations and study purpose. Due to
different characteristics inherit to different administrative
databases it would be imprudent to suggest preferred algo-
rithms for use outside of Canada, where other researchers
may be better informed on the characteristics of their own
databases under study. Rather, algorithms should be se-
lected based on study purpose and feasibility and weigh
the relative importance of accuracy measures that is most
important to a particular study. Incorrectly choosing the
wrong algorithm or prioritizing the wrong accuracy meas-
ure can lead to misclassification, which can lead to re-
duced power, loss of generalizability, as well as increased
bias, and possibly study cost [23].
Conclusions
Our study demonstrates that administrative data algo-
rithms can detect RA patients who receive regular primary
care with a high degree of accuracy. However, accuracy
varied slightly with the use of an alternative reference
standard. Our findings will inform future population-
based research and will serve to improve arthritis research
surveillance activities across Canada and abroad.
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